Stock REXAHN PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Rexahn Pharmaceuticals, Inc. Nyse

Equities

US7616401011

End-of-day quote Nyse
Other stock markets
- USD - Intraday chart for Rexahn Pharmaceuticals, Inc.

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ocuphire Pharma : to Participate in Upcoming Virtual HCW Conference in November
AQ
REXAHN PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Registrant's Certifying Accountant, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Amendment or Waiver to Code of Ethics, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Rexahn Pharmaceuticals : Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP
AQ
Rexahn Pharmaceuticals : Announces Expected Effectiveness of Reverse Stock Split and Merger Transaction with Ocuphire Pharma
AQ
REXAHN PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Rexahn Pharmaceuticals : Announces Stockholder Approval of All Proposals Required for Merger with Ocuphire Pharma
AQ
Rexahn Pharmaceuticals : XBRL Q3 2020
PU
REXAHN PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
REXAHN PHARMACEUTICALS, INC. : Other Events (form 8-K)
AQ
REXAHN PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
AQ
REXAHN PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
AQ
REXAHN PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
REXAHN PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
AQ
REXAHN PARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Rexahn Pharmaceuticals, Inc. - REXN
BU
REXAHN PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
REXAHN PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Rexahn and Ocuphire Enter into Definitive Merger Agreement
GL
REXAHN PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
REXAHN PHARMACEUTICALS, INC. : Termination of a Material Definitive Agreement (form 8-K)
AQ
REXAHN PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. Stock
  5. News Rexahn Pharmaceuticals, Inc.
  6. Press Releases